COMMUNIQUÉS West-GlobeNewswire

-
KFSHRC Performs Groundbreaking Procedure to Save Child’s Leg from Amputation
19/02/2025 -
InStride Health Partners with Aetna, Expanding Access to Specialty Mental Healthcare for Children and Families
19/02/2025 -
NAYA Biosciences Announces Nomination of New Board Members
19/02/2025 -
Ignite Proteomics Completes Acquisition of PLA Code 0249U for Its Advanced Proteomic Breast Cancer Assay
19/02/2025 -
Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference
19/02/2025 -
Lifeward Announces CEO Transition
19/02/2025 -
SANUWAVE Health to Participate in 37th Annual Roth Conference
19/02/2025 -
Ever After Foods and Bühler Collaborate to Scale Cultivated Meat Production and Distribution
19/02/2025 -
Inaugural Eye Health Summit Empowers Public with Integrative Vision Care Insights from Leading Experts
19/02/2025 -
GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
19/02/2025 -
Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies
19/02/2025 -
C3i Center, a Canadian company, receives approval from the EMA to manufacture cell therapy products for the European market
19/02/2025 -
Le Centre C3i, une compagnie canadienne, reçoit l'approbation de l’EMA pour fabriquer des produits de thérapie cellulaire pour le marché européen
19/02/2025 -
Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
19/02/2025 -
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET
18/02/2025 -
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET
18/02/2025 -
NeuroPace Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
18/02/2025 -
Lyell Immunopharma Announces Participation in Upcoming Investor Conferences
18/02/2025 -
InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
18/02/2025
Pages